-
Pooling of lupus can "catch" early skin cancerous: "Rapid Progression in DNA Damage"
Rahul Hajare
Commentary: Clinical Investigation
-
Pooling of lupus can "catch" early skin cancerous: "Rapid Progression in DNA Damage"
Rahul Hajare
Commentary: Clinical Investigation
-
Pooling of lupus can "catch" early skin cancerous: "Rapid Progression in DNA Damage"
Rahul Hajare
Commentary: Clinical Investigation
-
Pooling of lupus can "catch" early skin cancerous: "Rapid Progression in DNA Damage"
Rahul Hajare
Commentary: Clinical Investigation
-
Pooling of lupus can "catch" early skin cancerous: "Rapid Progression in DNA Damage"
Rahul Hajare
Commentary: Clinical Investigation
-
Pooling of lupus can "catch" early skin cancerous: "Rapid Progression in DNA Damage"
Rahul Hajare
Commentary: Clinical Investigation
-
Pooling of lupus can "catch" early skin cancerous: "Rapid Progression in DNA Damage"
Rahul Hajare
Commentary: Clinical Investigation
-
Pooling of lupus can "catch" early skin cancerous: "Rapid Progression in DNA Damage"
Rahul Hajare
Commentary: Clinical Investigation
-
Pridopidine in the pharmacological treatment of Huntingtons disease
Martin Michl, Katharina Schnopfhagen, Raphael M Bonelli
Review: Clinical Trail Outcomes: Clinical Investigation
-
Pridopidine in the pharmacological treatment of Huntingtons disease
Martin Michl, Katharina Schnopfhagen, Raphael M Bonelli
Review: Clinical Trail Outcomes: Clinical Investigation
-
Pridopidine in the pharmacological treatment of Huntingtons disease
Martin Michl, Katharina Schnopfhagen, Raphael M Bonelli
Review: Clinical Trail Outcomes: Clinical Investigation
-
Pridopidine in the pharmacological treatment of Huntingtons disease
Martin Michl, Katharina Schnopfhagen, Raphael M Bonelli
Review: Clinical Trail Outcomes: Clinical Investigation
-
Pridopidine in the pharmacological treatment of Huntingtons disease
Martin Michl, Katharina Schnopfhagen, Raphael M Bonelli
Review: Clinical Trail Outcomes: Clinical Investigation
-
Pridopidine in the pharmacological treatment of Huntingtons disease
Martin Michl, Katharina Schnopfhagen, Raphael M Bonelli
Review: Clinical Trail Outcomes: Clinical Investigation
-
Pridopidine in the pharmacological treatment of Huntingtons disease
Martin Michl, Katharina Schnopfhagen, Raphael M Bonelli
Review: Clinical Trail Outcomes: Clinical Investigation
-
Pridopidine in the pharmacological treatment of Huntingtons disease
Martin Michl, Katharina Schnopfhagen, Raphael M Bonelli
Review: Clinical Trail Outcomes: Clinical Investigation
-
Challenges in incentivizing the pharmaceutical industry to supporting pediatric oncology clinical trials
Paola Angelini, Kathryn Pritchard-Jones & Darren R Hargrave
Editorial: Clinical Investigation
-
Challenges in incentivizing the pharmaceutical industry to supporting pediatric oncology clinical trials
Paola Angelini, Kathryn Pritchard-Jones & Darren R Hargrave
Editorial: Clinical Investigation
-
Challenges in incentivizing the pharmaceutical industry to supporting pediatric oncology clinical trials
Paola Angelini, Kathryn Pritchard-Jones & Darren R Hargrave
Editorial: Clinical Investigation
-
Challenges in incentivizing the pharmaceutical industry to supporting pediatric oncology clinical trials
Paola Angelini, Kathryn Pritchard-Jones & Darren R Hargrave
Editorial: Clinical Investigation
-
Challenges in incentivizing the pharmaceutical industry to supporting pediatric oncology clinical trials
Paola Angelini, Kathryn Pritchard-Jones & Darren R Hargrave
Editorial: Clinical Investigation
-
Challenges in incentivizing the pharmaceutical industry to supporting pediatric oncology clinical trials
Paola Angelini, Kathryn Pritchard-Jones & Darren R Hargrave
Editorial: Clinical Investigation
-
Challenges in incentivizing the pharmaceutical industry to supporting pediatric oncology clinical trials
Paola Angelini, Kathryn Pritchard-Jones & Darren R Hargrave
Editorial: Clinical Investigation
-
Challenges in incentivizing the pharmaceutical industry to supporting pediatric oncology clinical trials
Paola Angelini, Kathryn Pritchard-Jones & Darren R Hargrave
Editorial: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 1, No 3
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 1, No 3
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 1, No 3
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 1, No 3
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 1, No 3
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 1, No 3
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 1, No 3
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 1, No 3
Acknowledgements: Clinical Investigation
-
Sodium,glucose cotransporter 2 inhibitors in the treatment of Type 2 diabetes: a review of Phase II and III trials
Mark S Kipnes
Review Article: Clinical Investigation
-
Sodium,glucose cotransporter 2 inhibitors in the treatment of Type 2 diabetes: a review of Phase II and III trials
Mark S Kipnes
Review Article: Clinical Investigation
-
Sodium,glucose cotransporter 2 inhibitors in the treatment of Type 2 diabetes: a review of Phase II and III trials
Mark S Kipnes
Review Article: Clinical Investigation
-
Sodium,glucose cotransporter 2 inhibitors in the treatment of Type 2 diabetes: a review of Phase II and III trials
Mark S Kipnes
Review Article: Clinical Investigation
-
Sodium,glucose cotransporter 2 inhibitors in the treatment of Type 2 diabetes: a review of Phase II and III trials
Mark S Kipnes
Review Article: Clinical Investigation
-
Sodium,glucose cotransporter 2 inhibitors in the treatment of Type 2 diabetes: a review of Phase II and III trials
Mark S Kipnes
Review Article: Clinical Investigation
-
Sodium,glucose cotransporter 2 inhibitors in the treatment of Type 2 diabetes: a review of Phase II and III trials
Mark S Kipnes
Review Article: Clinical Investigation
-
Sodium,glucose cotransporter 2 inhibitors in the treatment of Type 2 diabetes: a review of Phase II and III trials
Mark S Kipnes
Review Article: Clinical Investigation